Toll-like Receptor 4 Signaling and Downstream Neutrophilic Inflammation Mediate Endotoxemia-Enhanced Blood-Labyrinth Barrier Trafficking

Zachary D. Urdang, Jessica L. Bills, David Y. Cahana, Leslie L. Muldoon, Edward A. Neuwelt

Research output: Contribution to journalArticle

Abstract

Hypothesis: Both toll-like receptor 4 (TLR4) and downstream neutrophil activity are required for endotoxemiaenhanced blood-labyrinth barrier (BLB) trafficking. Background: Aminoglycoside and cisplatin are valuable clinical therapies; however, these drugs often cause life-long hearing loss. Endotoxemia enhances the ototoxicity of aminoglycosides and cisplatin in a TLR4 dependent mechanism for which downstream proinflammatory signaling orchestrates effector immune cells including neutrophils. Neutrophil-mediated vascular injury (NMVI) can enhance molecular trafficking across endothelial barriers and may contribute to endotoxemiaenhanced drug-induced ototoxicity. Methods: Lipopolysaccharide (LPS) hypo-responsive TLR4-KO mice and congenitally neutropenic granulocyte colonystimulating factor (GCSF) GCSF-KO mice were studied to investigate the relative contributions of TLR4 signaling and downstream neutrophil activity to endotoxemia-enhanced BLB trafficking. C57Bl/6 wild-type mice were used as a positive control. Mice were treated with LPS and 24 hours later cochleae were analyzed for gene transcription of innate inflammatory cytokine/chemokine signaling molecules, neutrophil recruitment, and vascular trafficking of the paracellular tracer biocytin-TMR. Results: Cochlear transcription of innate proinflammatory cytokines/chemokines was increased in endotoxemic C57Bl/6 and GCSF-KO, but not in TLR4-KO mice. More neutrophils were recruited to endotoxemic C57Bl/6 cochleae compared with both TLR4 and GCSF-KO cochleae. Endotoxemia enhanced BLB trafficking of biocytin-TMR in endotoxemic C57Bl/6 cochleae and this was attenuated in both TLR4 and GCSF-KO mice. Conclusion: Together these results suggest that TLR4-mediated innate immunity cytokine/chemokine signaling alone is not sufficient for endotoxemia-enhanced trafficking of biocytin-TMR and that downstream neutrophil activity is required to enhance BLB trafficking. Clinically, targeting neutrophilic inflammation could protect hearing during aminoglycoside, cisplatin, or other ototoxic drug therapies.

Original languageEnglish (US)
JournalOtology and Neurotology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Toll-Like Receptor 4
Endotoxemia
Inner Ear
Cochlea
Granulocytes
Neutrophils
Inflammation
Aminoglycosides
Chemokines
Cisplatin
Cytokines
Lipopolysaccharides
Neutrophil Infiltration
Vascular System Injuries
Hearing Loss
Innate Immunity
Pharmaceutical Preparations
Hearing
Blood Vessels
Drug Therapy

Keywords

  • Aminoglycoside
  • Blood-labyrinth barrier
  • Cisplatin
  • Innate inflammation
  • Neutrophil
  • Ototoxicity
  • Reactive oxygen species
  • Sepsis
  • Systemic inflammatory response syndrome

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Sensory Systems
  • Clinical Neurology

Cite this

Toll-like Receptor 4 Signaling and Downstream Neutrophilic Inflammation Mediate Endotoxemia-Enhanced Blood-Labyrinth Barrier Trafficking. / Urdang, Zachary D.; Bills, Jessica L.; Cahana, David Y.; Muldoon, Leslie L.; Neuwelt, Edward A.

In: Otology and Neurotology, 01.01.2019.

Research output: Contribution to journalArticle

@article{445f98b001e24b62a93ea1f6a0c51a31,
title = "Toll-like Receptor 4 Signaling and Downstream Neutrophilic Inflammation Mediate Endotoxemia-Enhanced Blood-Labyrinth Barrier Trafficking",
abstract = "Hypothesis: Both toll-like receptor 4 (TLR4) and downstream neutrophil activity are required for endotoxemiaenhanced blood-labyrinth barrier (BLB) trafficking. Background: Aminoglycoside and cisplatin are valuable clinical therapies; however, these drugs often cause life-long hearing loss. Endotoxemia enhances the ototoxicity of aminoglycosides and cisplatin in a TLR4 dependent mechanism for which downstream proinflammatory signaling orchestrates effector immune cells including neutrophils. Neutrophil-mediated vascular injury (NMVI) can enhance molecular trafficking across endothelial barriers and may contribute to endotoxemiaenhanced drug-induced ototoxicity. Methods: Lipopolysaccharide (LPS) hypo-responsive TLR4-KO mice and congenitally neutropenic granulocyte colonystimulating factor (GCSF) GCSF-KO mice were studied to investigate the relative contributions of TLR4 signaling and downstream neutrophil activity to endotoxemia-enhanced BLB trafficking. C57Bl/6 wild-type mice were used as a positive control. Mice were treated with LPS and 24 hours later cochleae were analyzed for gene transcription of innate inflammatory cytokine/chemokine signaling molecules, neutrophil recruitment, and vascular trafficking of the paracellular tracer biocytin-TMR. Results: Cochlear transcription of innate proinflammatory cytokines/chemokines was increased in endotoxemic C57Bl/6 and GCSF-KO, but not in TLR4-KO mice. More neutrophils were recruited to endotoxemic C57Bl/6 cochleae compared with both TLR4 and GCSF-KO cochleae. Endotoxemia enhanced BLB trafficking of biocytin-TMR in endotoxemic C57Bl/6 cochleae and this was attenuated in both TLR4 and GCSF-KO mice. Conclusion: Together these results suggest that TLR4-mediated innate immunity cytokine/chemokine signaling alone is not sufficient for endotoxemia-enhanced trafficking of biocytin-TMR and that downstream neutrophil activity is required to enhance BLB trafficking. Clinically, targeting neutrophilic inflammation could protect hearing during aminoglycoside, cisplatin, or other ototoxic drug therapies.",
keywords = "Aminoglycoside, Blood-labyrinth barrier, Cisplatin, Innate inflammation, Neutrophil, Ototoxicity, Reactive oxygen species, Sepsis, Systemic inflammatory response syndrome",
author = "Urdang, {Zachary D.} and Bills, {Jessica L.} and Cahana, {David Y.} and Muldoon, {Leslie L.} and Neuwelt, {Edward A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/MAO.0000000000002447",
language = "English (US)",
journal = "Otology and Neurotology",
issn = "1531-7129",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Toll-like Receptor 4 Signaling and Downstream Neutrophilic Inflammation Mediate Endotoxemia-Enhanced Blood-Labyrinth Barrier Trafficking

AU - Urdang, Zachary D.

AU - Bills, Jessica L.

AU - Cahana, David Y.

AU - Muldoon, Leslie L.

AU - Neuwelt, Edward A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hypothesis: Both toll-like receptor 4 (TLR4) and downstream neutrophil activity are required for endotoxemiaenhanced blood-labyrinth barrier (BLB) trafficking. Background: Aminoglycoside and cisplatin are valuable clinical therapies; however, these drugs often cause life-long hearing loss. Endotoxemia enhances the ototoxicity of aminoglycosides and cisplatin in a TLR4 dependent mechanism for which downstream proinflammatory signaling orchestrates effector immune cells including neutrophils. Neutrophil-mediated vascular injury (NMVI) can enhance molecular trafficking across endothelial barriers and may contribute to endotoxemiaenhanced drug-induced ototoxicity. Methods: Lipopolysaccharide (LPS) hypo-responsive TLR4-KO mice and congenitally neutropenic granulocyte colonystimulating factor (GCSF) GCSF-KO mice were studied to investigate the relative contributions of TLR4 signaling and downstream neutrophil activity to endotoxemia-enhanced BLB trafficking. C57Bl/6 wild-type mice were used as a positive control. Mice were treated with LPS and 24 hours later cochleae were analyzed for gene transcription of innate inflammatory cytokine/chemokine signaling molecules, neutrophil recruitment, and vascular trafficking of the paracellular tracer biocytin-TMR. Results: Cochlear transcription of innate proinflammatory cytokines/chemokines was increased in endotoxemic C57Bl/6 and GCSF-KO, but not in TLR4-KO mice. More neutrophils were recruited to endotoxemic C57Bl/6 cochleae compared with both TLR4 and GCSF-KO cochleae. Endotoxemia enhanced BLB trafficking of biocytin-TMR in endotoxemic C57Bl/6 cochleae and this was attenuated in both TLR4 and GCSF-KO mice. Conclusion: Together these results suggest that TLR4-mediated innate immunity cytokine/chemokine signaling alone is not sufficient for endotoxemia-enhanced trafficking of biocytin-TMR and that downstream neutrophil activity is required to enhance BLB trafficking. Clinically, targeting neutrophilic inflammation could protect hearing during aminoglycoside, cisplatin, or other ototoxic drug therapies.

AB - Hypothesis: Both toll-like receptor 4 (TLR4) and downstream neutrophil activity are required for endotoxemiaenhanced blood-labyrinth barrier (BLB) trafficking. Background: Aminoglycoside and cisplatin are valuable clinical therapies; however, these drugs often cause life-long hearing loss. Endotoxemia enhances the ototoxicity of aminoglycosides and cisplatin in a TLR4 dependent mechanism for which downstream proinflammatory signaling orchestrates effector immune cells including neutrophils. Neutrophil-mediated vascular injury (NMVI) can enhance molecular trafficking across endothelial barriers and may contribute to endotoxemiaenhanced drug-induced ototoxicity. Methods: Lipopolysaccharide (LPS) hypo-responsive TLR4-KO mice and congenitally neutropenic granulocyte colonystimulating factor (GCSF) GCSF-KO mice were studied to investigate the relative contributions of TLR4 signaling and downstream neutrophil activity to endotoxemia-enhanced BLB trafficking. C57Bl/6 wild-type mice were used as a positive control. Mice were treated with LPS and 24 hours later cochleae were analyzed for gene transcription of innate inflammatory cytokine/chemokine signaling molecules, neutrophil recruitment, and vascular trafficking of the paracellular tracer biocytin-TMR. Results: Cochlear transcription of innate proinflammatory cytokines/chemokines was increased in endotoxemic C57Bl/6 and GCSF-KO, but not in TLR4-KO mice. More neutrophils were recruited to endotoxemic C57Bl/6 cochleae compared with both TLR4 and GCSF-KO cochleae. Endotoxemia enhanced BLB trafficking of biocytin-TMR in endotoxemic C57Bl/6 cochleae and this was attenuated in both TLR4 and GCSF-KO mice. Conclusion: Together these results suggest that TLR4-mediated innate immunity cytokine/chemokine signaling alone is not sufficient for endotoxemia-enhanced trafficking of biocytin-TMR and that downstream neutrophil activity is required to enhance BLB trafficking. Clinically, targeting neutrophilic inflammation could protect hearing during aminoglycoside, cisplatin, or other ototoxic drug therapies.

KW - Aminoglycoside

KW - Blood-labyrinth barrier

KW - Cisplatin

KW - Innate inflammation

KW - Neutrophil

KW - Ototoxicity

KW - Reactive oxygen species

KW - Sepsis

KW - Systemic inflammatory response syndrome

UR - http://www.scopus.com/inward/record.url?scp=85072283183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072283183&partnerID=8YFLogxK

U2 - 10.1097/MAO.0000000000002447

DO - 10.1097/MAO.0000000000002447

M3 - Article

AN - SCOPUS:85072283183

JO - Otology and Neurotology

JF - Otology and Neurotology

SN - 1531-7129

ER -